The blood-brain barrier (BBB) is a physical, metabolic, and transport barrier between the systemic blood circulation and the central nervous system (CNS). The transfer of substances from blood to the CNS tissues and vice versa that critically maintains CNS homeostasis is tightly regulated through this complex vascular network in order to maintain optimal levels of essential nutrients and neurotransmitters in the CNS, in addition to the critical role of protecting the CNS against exogenous neurotoxins. 1,2 Access of immune cells into the CNS through the BBB is restricted but not completely prohibited. The mechanisms of immune cell trafficking in the CNS are very complicated, and so many factors such as the variety of immune cell types, adhesion molecules, and pro-/anti-inflammatory cytokines play roles to maintain the CNS immune system. 3 Therefore, it may be important to study the BBB in order to understand the inflammatory events related to multiple sclerosis (MS) pathogenesis and to develop immune suppressing/modulating drugs. What about neurodegeneration? Does studying the BBB help us to provide new insight into neurodegeneration? I would say "No" in my opinion.
The disruption of the BBB in MS has been known as a prerequisite for developing the inflammatory events of the disease since the late 1980s 4 and magnetic resonance imaging (MRI) T2 lesions and gadolinium-enhancing lesions based on the high BBB permeability have been used as a primary outcome measure in the numbers of clinical studies because of their higher sensitivity to disease inflammation activity than clinical assessment of relapses. These inflammation measures have been successfully providing a good surrogacy of treatment effect in relapsing-remitting multiple sclerosis (RRMS), whereas their value in a progressive disease course remains elusive. 5 Although less pronounced, neuroinflammatory change and BBB breakdown seem also a common hallmark of many chronic neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and Huntington disease. 6 However, it still remains unknown whether BBB breakdown is one of the initial events leading to CNS cell damage or whether it is a downstream consequence.
There is a similar debate about MS etiology whether or not MS is a primary autoimmune disease as generally held, or if it is actually a primary neurodegenerative disorder in reality, 7, 8 although the real cause and pathogenesis of MS still remain unknown. The concept that MS is an autoimmune disease is largely based on an artificial animal model of experimentally induced inflammation against myelin by priming myelinrelated peptide reactive lymphocytes (experimental autoimmune encephalomyelitis, EAE). EAE resembles MS on the surface; thus, this animal model has been largely used to study the immunopathological side of the disease, including recent studies on the BBB, with largely consistent laboratory and clinical observations. However, the assumption of a primary immunopathogenesis of the disease may be flawed and, in fact, has been failing to deliver an effective therapy for the progressive course of MS over 30 years. Therefore, MS research has been refocused on the role of axonal pathology and neurodegeneration as a potential cause of permanent neurological disability in MS patients since the late 1990s. Almost two decades of studies on early MS lesions have revealed more evidence to support that MS may be a primary neurodegenerative disease. The earliest myelin abnormalities may begin at the inner myelin sheath surrounding still-myelinated axons while the outer myelin wraps are often still intact. 9 Also, active demyelinating lesions show preferential loss of myelin-associated glycoprotein (MAG) that is expressed on the inner periaxonal wraps of myelin. 10 How could these happen if extrinsic immune cellor antibody-mediated insults were brought from the peripheral circulation through the BBB into the CNS and were primarily responsible for such early myelin changes, especially in the innermost regions? Moreover, such early myelin damage is often seen beyond areas of maximum inflammation, suggesting that demyelination may precede inflammation in some cases. 9 On the assumption that a series of pathogenic events, autoimmune activation, BBB disruption, demyelination, and axonal transection are real pathological features of early MS, anti-inflammatory treatment of the relapsing-remitting phase should have indirect effects on preventing subsequent demyelination and axonal injury. However, unfortunately none of previous disease-modifying therapies (DMTs) by immunomodulation, such as interferon beta-1a (IFNβ-1a, Avonex), IFNβ-1b (Betaseron), glatiramer acetate (GA, Copaxone), mitoxantrone (MITO), and the monoclonal antibody against the leukocyte VLA-4 (VCAM-1 ligand, natalizumab), slowed the progressive phase of MS. In particular, natalizumab was designed to block the immunocompetent T cell trafficking into the CNS; therefore, this drug was predicted to be the leading drug for MS as a BBB drug until its recall for clinical use after two patients with MS developed progressive multifocal leukoencephalopathy (PML) while being treated. The lessons from the natalizumab trials are that aggressive immunotherapy in MS to block T cell trafficking in the CNS, and by extension BBB modification, can be very risky. Immunotherapy in MS is yet to prove its value as a true cure for the disease. Reducing relapse is not necessary for an effective strategy to prevent serious and chronic disability in MS, based on recent epidemiological models 11, 12 . Anti-inflammatory therapy may only have a marginal therapeutic role in neurodegenerative diseases by limiting the secondary inflammation following primary myelin, axonal, and neuronal injury. What is currently lacking is neurodegeneration-focused research to identify the specific targets. There might be an intrinsic cause of tissue degeneration such as mitochondrial dysfunction 13 and glutamate excitotoxicity 14 in the initial MS pathogenesis. Now our major challenge for MS research is to elucidate and understand the real cause of MS. The study for the non-immune disease mechanisms and therapeutic options has been left unexplored; thus, we should move our research focus from the immunopathogenesis to neurodegenerative mechanisms to produce more creative approaches.
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